(Adds detail, Wesfarmers comment)
July 12 (Reuters) - Australian Pharmaceutical Industries (API) on Monday said it has received an unsolicited, non-binding buyout proposal from retail conglomerate Wesfarmers (WES) that values the pharmacy chain operator at A$679.9 mln ($508.9 mln).
Under the offer, shareholders of the pharmaceutical firm would get A$1.38 apiece, a premium of 20.5% to API's last close of A$1.145 on Friday.
The deal would give Wesfarmers access to API's network of retail stores, skincare clinics, and a distribution network of pharmaceutical and healthcare products, marking Wesfarmers' entry into the country's health sector.
"If the proposal is successful, API would form the basis of a new healthcare division of Wesfarmers and a base from which to invest and develop capabilities in the health and wellbeing sector," Wesfarmers said in a separate exchange filing.
API's major shareholder Washington H Soul Pattinson Co (SOL) , which owns 19.3% in the pharmaceutical firm, has indicated its support for the proposal and agreed to vote in favour of it, the retail conglomerate added.
Earlier, API said in a separate filing that it would stop manufacturing personal care and over-the-counter products in New Zealand in a move to simplify its business, and flagged a hit to its earnings for the full-year ending Aug. 31.
($1 = 1.3360 Australian dollars)
- Forums
- ASX - By Stock
- News: API UPDATE 1-Australian Pharmaceutical Industries gets $509 mln buyout proposal from...
(Adds detail, Wesfarmers comment) July 12 (Reuters) -...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add API (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online